Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker
D Binder, AC Buckendahl, RH Hübner, P Schlattmann… - Medical Oncology, 2012 - Springer
Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker
D Binder, A Buckendahl, R Hübner… - Medical …, 2012 - search.proquest.com
Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker
D Binder, AC Buckendahl… - Medical oncology …, 2012 - pubmed.ncbi.nlm.nih.gov
Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker
D Binder, AC Buckendahl, RH Hübner, P Schlattmann… - Medical Oncology, 2012 - infona.pl
Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.
D Binder, AC Buckendahl, RH Hübner… - Medical Oncology …, 2010 - europepmc.org
Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …